TheraRadar
← Back
Data updated: May 24, 2026

B BRAUN MEDICAL

Pharma

B BRAUN MEDICAL is a pharmaceutical company focused on Neurology, Infectious Disease, Dermatology. Key products include PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.

2015
Since
16
Drugs
-
Trials
3
New Drugs (2yr)
Modality:
3 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Jun 10, 2026 — Oclaiz (CAM2029, octreotide subcutaneous depot)
15d
Jun 18, 2026 — Nilopki (XS003, nilotinib)
Jun 29, 2026 — ZORYVE (roflumilast) cream 0.3%

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Neurology 31%
3 drugs
Infectious Disease 29%
2 drugs Phase 1: 5
Dermatology 20%
2 drugs
Cardiovascular 10%
1 drugs
Metabolic 10%
1 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
0
Phase 2
5
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER leads revenue
  • 2 key drugs tracked

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling